Literature DB >> 24027432

COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis.

Jing Shao1, Yong Teng, Ravi Padia, Sungguan Hong, Hyangsoon Noh, Xiayang Xie, Jeff S Mumm, Zheng Dong, Han-Fei Ding, John Cowell, Jaejik Kim, Jiahuai Han, Shuang Huang.   

Abstract

High abundance of c-Jun is detected in invasive breast cancer cells and aggressive breast tumor malignancies. Here, we demonstrate that a major cause of high c-Jun abundance in invasive breast cancer cells is prolonged c-Jun protein stability owing to poor poly-ubiquitination of c-Jun. Among the known c-Jun-targeting E3 ligases, we identified constitutive photomorphogenesis protein 1 (COP1) as an E3 ligase responsible for c-Jun degradation in less invasive breast cancer cells because depletion of COP1 reduced c-Jun poly-ubiquitination leading to the stabilization of c-Jun protein. In a panel of breast cancer cell lines, we observed an inverse association between the levels of COP1 and c-Jun. However, overexpressing COP1 alone was unable to decrease c-Jun level in invasive breast cancer cells, indicating that efficient c-Jun protein degradation necessitates an additional event. Indeed, we found that glycogen synthase kinase 3 (GSK3) inhibitors elevated c-Jun abundance in less invasive breast cancer cells and that GSK3β nonphosphorylable c-Jun-T239A mutant displayed greater protein stability and poorer poly-ubiquitination compared to the wild-type c-Jun. The ability of simultaneously enforced expression of COP1 and constitutively active GSK3β to decrease c-Jun abundance in invasive breast cancer cells allowed us to conclude that c-Jun is negatively regulated through the coordinated action of COP1 and GSK3β. Importantly, co-expressing COP1 and active GSK3β blocked in vitro cell growth/migration and in vivo metastasis of invasive breast cancer cells. Gene expression profiling of breast tumor specimens further revealed that higher COP1 expression correlated with better recurrence-free survival. Our study supports the notion that COP1 is a suppressor of breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24027432      PMCID: PMC3769886          DOI: 10.1593/neo.13966

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  35 in total

1.  Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4.

Authors:  D G Tiniakos; L E Scott; I P Corbett; N H Piggott; C H Horne
Journal:  J Pathol       Date:  1994-01       Impact factor: 7.996

2.  JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.

Authors:  B Dérijard; M Hibi; I H Wu; T Barrett; B Su; T Deng; M Karin; R J Davis
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

3.  cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.

Authors:  L M Smith; S C Wise; D T Hendricks; A L Sabichi; T Bos; P Reddy; P H Brown; M J Birrer
Journal:  Oncogene       Date:  1999-10-28       Impact factor: 9.867

4.  COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.

Authors:  David Dornan; Sheila Bheddah; Kim Newton; William Ince; Gretchen D Frantz; Patrick Dowd; Hartmut Koeppen; Vishva M Dixit; Dorothy M French
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

5.  Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch.

Authors:  Min Gao; Tord Labuda; Ying Xia; Ewen Gallagher; Deyu Fang; Yun-Cai Liu; Michael Karin
Journal:  Science       Date:  2004-09-09       Impact factor: 47.728

6.  The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling.

Authors:  Abdolrahman S Nateri; Lluís Riera-Sans; Clive Da Costa; Axel Behrens
Journal:  Science       Date:  2004-01-22       Impact factor: 47.728

7.  Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase.

Authors:  Ingrid E Wertz; Karen M O'Rourke; Zemin Zhang; David Dornan; David Arnott; Raymond J Deshaies; Vishva M Dixit
Journal:  Science       Date:  2004-01-22       Impact factor: 47.728

8.  Survival regulation in pancreatic cancer cells by c-Jun.

Authors:  Yoshiyuki Okutomi; Yuji Shino; Fumitake Komoda; Tatsuya Hirano; Takeshi Ishihara; Taketo Yamaguchi; Hiromitsu Saisho; Hiroshi Shirasawa
Journal:  Int J Oncol       Date:  2003-10       Impact factor: 5.650

9.  Casein kinase II is a negative regulator of c-Jun DNA binding and AP-1 activity.

Authors:  A Lin; J Frost; T Deng; T Smeal; N al-Alawi; U Kikkawa; T Hunter; D Brenner; M Karin
Journal:  Cell       Date:  1992-09-04       Impact factor: 41.582

10.  ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.

Authors:  Christoforos Thomas; Gayani Rajapaksa; Fotis Nikolos; Ruixin Hao; Anne Katchy; Catherine W McCollum; Maria Bondesson; Phil Quinlan; Alastair Thompson; Savitri Krishnamurthy; Francisco J Esteva; Jan-Åke Gustafsson
Journal:  Breast Cancer Res       Date:  2012-11-16       Impact factor: 6.466

View more
  28 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  Extracellular signal-regulated kinase signaling regulates the opposing roles of JUN family transcription factors at ETS/AP-1 sites and in cell migration.

Authors:  Nagarathinam Selvaraj; Justin A Budka; Mary W Ferris; Joshua P Plotnik; Peter C Hollenhorst
Journal:  Mol Cell Biol       Date:  2014-10-20       Impact factor: 4.272

Review 3.  Role of E3 ubiquitin ligases in gastric cancer.

Authors:  Ya-Chao Hou; Jing-Yu Deng
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

4.  Correlation of constitutive photomorphogenic 1 (COP1) and p27 tumor suppressor protein expression in ovarian cancer.

Authors:  Eun-Ji Ko; Young Lim Oh; Heung Yeol Kim; Wan Kyu Eo; Hongbae Kim; Ki Hyung Kim; Suk Bong Koh; Mee Sun Ock; Yung Hyun Choi; Ari Kim; Hyun Ho Choi; Eun Joo Park; Hee-Jae Cha
Journal:  Genes Genomics       Date:  2019-04-26       Impact factor: 1.839

5.  Timeless-Stimulated miR-5188-FOXO1/β-Catenin-c-Jun Feedback Loop Promotes Stemness via Ubiquitination of β-Catenin in Breast Cancer.

Authors:  Yujiao Zou; Xian Lin; Junguo Bu; Zelong Lin; Yanjuan Chen; Yunhui Qiu; Haiyue Mo; Yao Tang; Weiyi Fang; Ziqing Wu
Journal:  Mol Ther       Date:  2019-09-03       Impact factor: 11.454

6.  Noncanonical role of Arabidopsis COP1/SPA complex in repressing BIN2-mediated PIF3 phosphorylation and degradation in darkness.

Authors:  Jun-Jie Ling; Jian Li; Danmeng Zhu; Xing Wang Deng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-14       Impact factor: 11.205

7.  The Ubiquitin Ligase COP1 Promotes Glioma Cell Proliferation by Preferentially Downregulating Tumor Suppressor p53.

Authors:  Shenshan Zou; Yufu Zhu; Bin Wang; Fengyuan Qian; Xiang Zhang; Lei Wang; Chunling Fu; Hanmo Bao; Manyi Xie; Shangfeng Gao; Rutong Yu; Hengliang Shi
Journal:  Mol Neurobiol       Date:  2016-08-17       Impact factor: 5.590

8.  Enhanced cell-specific ablation in zebrafish using a triple mutant of Escherichia coli nitroreductase.

Authors:  Jonathan R Mathias; Zhanying Zhang; Meera T Saxena; Jeff S Mumm
Journal:  Zebrafish       Date:  2014-01-15       Impact factor: 1.985

9.  SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

Authors:  Sungguan Hong; Hyangsoon Noh; Yong Teng; Jing Shao; Hina Rehmani; Han-Fei Ding; Zheng Dong; Shi-Bing Su; Huidong Shi; Jaejik Kim; Shuang Huang
Journal:  Neoplasia       Date:  2014-04-18       Impact factor: 5.715

10.  Ubiquitin-Specific Protease USP6 Regulates the Stability of the c-Jun Protein.

Authors:  Lisheng Li; Hong Yang; Yan He; Ting Li; Jinan Feng; Wanze Chen; Lu Ao; Xuying Shi; Yingying Lin; Haoyun Liu; Enrun Zheng; Qiaofa Lin; Jingjing Bu; Yanhua Zeng; Min Zheng; Yan Xu; Zhijun Liao; Jiacheng Lin; Dexin Lin
Journal:  Mol Cell Biol       Date:  2017-12-29       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.